Thakkar JP, Kumthekar P, Dixit KS et al (2020) Leptomeningeal metastasis from solid tumors. J Neurol Sci 411:116706. https://doi.org/10.1016/j.jns.2020.116706
Freilich RJ, Krol G, Deangelis LM (1995) Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 38:51–57. https://doi.org/10.1002/ana.410380111
CAS Article PubMed Google Scholar
Sener U, Kumthekar P, Boire A (2021) Advances in the diagnosis, evaluation, and management of leptomeningeal disease. Neuro-Oncol Adv 3:v86–v95. https://doi.org/10.1093/noajnl/vdab108
Wang N, Bertalan MS, Brastianos PK (2018) Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer 124:21–35. https://doi.org/10.1002/cncr.30911
Beauchesne P (2010) Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 11:871–879. https://doi.org/10.1016/S1470-2045(10)70034-6
CAS Article PubMed Google Scholar
Khang M, Bindra RS, Mark Saltzman W (2022) Intrathecal delivery and its applications in leptomeningeal disease. Adv Drug Deliv Rev 186:114338. https://doi.org/10.1016/j.addr.2022.114338
CAS Article PubMed Google Scholar
Shinoura N, Tabei Y, Yamada R et al (2008) Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors. J Neuro-Oncol 87:309–316. https://doi.org/10.1007/s11060-007-9511-3
Edwards MS, Levin VA, Seager ML, Wilson CB (1981) Intrathecal chemotherapy for leptomeningeal dissemination of medulloblastoma. Pediatr Neurosurg 8:444–451. https://doi.org/10.1159/000120013
Scott BJ, van Vugt VA, Rush T et al (2014) Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neuro-Oncol 119:361–368. https://doi.org/10.1007/s11060-014-1486-2
de Oca M, Delgado M, Cacho Díaz B, Santos Zambrano J et al (2018) The comparative treatment of intraventricular chemotherapy by ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis. Front Oncol 8:1–7. https://doi.org/10.3389/fonc.2018.00509
Carausu M, Carton M, Darlix A et al (2021) Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open 6:100150. https://doi.org/10.1016/j.esmoop.2021.100150
CAS Article PubMed PubMed Central Google Scholar
Pan Z, Yang G, He H et al (2020) Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study. Ther Adv Med Oncol 12:1758835920937953. https://doi.org/10.1177/1758835920937953
CAS Article PubMed PubMed Central Google Scholar
Hou L, Han W, Jin J et al (2021) Clinical efficacy and safety of different doses of intrathecal methotrexate in the treatment of leptomeningeal carcinomatosis: a prospective and single-arm study. Jpn J Clin Oncol 51:1715–1722. https://doi.org/10.1093/jjco/hyab155
Glitza IC, Rohlfs M, Guha-Thakurta N et al (2018) Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3:e000283. https://doi.org/10.1136/esmoopen-2017-000283
Article PubMed PubMed Central Google Scholar
Bonneau C, Paintaud G, Trédan O et al (2018) Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer 95:75–84. https://doi.org/10.1016/j.ejca.2018.02.032
CAS Article PubMed Google Scholar
Figura NB, Long W, Yu M et al (2018) Intrathecal trastuzumab in the management of HER2 + breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat 169:391–396. https://doi.org/10.1007/s10549-018-4684-3
CAS Article PubMed Google Scholar
Figura NB, Rizk VT, Mohammadi H et al (2019) Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat 175:781–788. https://doi.org/10.1007/s10549-019-05170-7
CAS Article PubMed Google Scholar
Lee Y-C, Hsieh C-C, Chuang J-P, Li C-Y (2017) The necessity of intrathecal chemotherapy for the treatment of breast cancer patients with leptomeningeal metastasis: a systematic review and pooled analysis. Curr Probl Cancer 41:355–370. https://doi.org/10.1016/j.currproblcancer.2017.07.001
Zagouri F, Zoumpourlis P, Le Rhun E et al (2020) Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: a metanalysis with meta-regression. Cancer Treat Rev 88:102046. https://doi.org/10.1016/j.ctrv.2020.102046
CAS Article PubMed Google Scholar
Tricco AC, Lillie E, Zarin W et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467–473. https://doi.org/10.7326/M18-0850
Chamberlain M, Junck L, Brandsma D et al (2016) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology 19:183. https://doi.org/10.1093/neuonc/now183
Howick J, Chalmers I, Glasziou P, et al (2011) Explanation of the 2011 oxford centre for evidence-based medicine (OCEBM) Levels of evidence (Background Document). In: Oxford Cent. Evidence-Based Med. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
Moola S, Munn Z, Tufanaru C et al (2020) Chapter 7: systematic reviews of etiology and risk. In: Aromataris E, Munn Z (eds) JBI manual for evidence synthesis. JBI, Adelaide
Levin VA, Chamberlain M, Silver P et al (1989) Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol 23:301–307. https://doi.org/10.1007/BF00292408
CAS Article PubMed Google Scholar
Glantz MJ, Cole BF, Recht L et al (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16:1561–1567. https://doi.org/10.1200/JCO.1998.16.4.1561
CAS Article PubMed Google Scholar
Witham TF, Fukui MB, Meltzer CC et al (1999) Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. Cancer 86:1347–1353. https://doi.org/10.1002/(SICI)1097-0142(19991001)86:7%3c1347::AID-CNCR34%3e3.0.CO;2-M
CAS Article PubMed Google Scholar
Esteva FJ, Soh L-T, Holmes FA et al (2000) Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 46:382–386. https://doi.org/10.1007/s002800000173
CAS Article PubMed Google Scholar
Sandberg DI, Bilsky MH, Souweidane MM et al (2000) Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47:49–55. https://doi.org/10.1097/00006123-200007000-00011
CAS Article PubMed Google Scholar
Kim D-Y (2003) Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 33:608–612. https://doi.org/10.1093/jjco/hyg118
Yoshimura J, Nishiyama K, Mori H et al (2008) Intrathecal chemotherapy for refractory disseminated medulloblastoma. Child’s Nerv Syst 24:581–585. https://doi.org/10.1007/s00381-007-0538-8
Clatot F, Philippin-Lauridant G, Ouvrier M-J et al (2009) Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neuro-Oncol 95:421–426. https://doi.org/10.1007/s11060-009-9940-2
Calvo-Villas J-M, Fernández JA, De La Fuente I et al (2010) Intrathecal liposomal cytarabine for treatment of leptomeningeal involvement in transformed (Richter’s syndrome) and non-transformed B-cell chronic lymphocytic leukaemia in Spain: a report of seven cases. Br J Haematol 150:618–620. https://doi.org/10.1111/j.1365-2141.2010.08238.x
CAS Article PubMed Google Scholar
Gwak H-S, Lee C-H, Yang HS et al (2011) Chemoport with a non-collapsible chamber as a replacement for an Ommaya reservoir in the treatment of leptomeningeal carcinomatosis. Acta Neurochir 153:1971–1978. https://doi.org/10.1007/s00701-011-1086-2
Chamberlain MC (2012) Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neuro-Oncol 109:143–148. https://doi.org/10.1007/s11060-012-0880-x
Comte A, Jdid W, Guilhaume MN et al (2013) Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neuro-Oncol 115:445–452. https://doi.org/10.1007/s11060-013-1244-x
Fusco JP, Castañón E, Carranza OE et al (2013) Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study. J Neuro-Oncol 115:429–435. https://doi.org/10.1007/s11060-013-1241-0
Gaviani P, Corsini E, Salmaggi A et al (2013) Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience. Neurol Sci 34:2151–2157. https://doi.org/10.1007/s10072-013-1358-0
CAS Article PubMed Google Scholar
Niwińska A, Rudnicka H, Murawska M (2015) breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy. Clin Breast Cancer 15:66–72. https://doi.org/10.1016/j.clbc.2014.07.004
CAS Article PubMed Google Scholar
Cho K-M, Kim YJ, Kim SH et al (2015) Salvage treatment with intracerebrospinal fluid thiotepa in patients with leptomeningeal metastasis after failure of methotrexate-based treatment. Anticancer Res 35:5631–5638
留言 (0)